Key Takeaways
- Biological AI models are most mature in protein‑centric tasks (structure prediction, function annotation, molecular design) thanks to long‑standing curated repositories such as the Protein Data Bank and UniProt.
- Progress lags in data‑sparse domains like single‑cell biology, where limited and non‑standardised datasets hinder model development and validation.
- The EU possesses strong scientific expertise and high‑performance computing capacity (EuroHPC JU, AI Factories), yet intra‑EU collaboration remains weak compared with ties to the US, China, and the UK.
- High‑profile models such as AlphaFold and ESM3 achieve high domain maturity but sit at low‑to‑mid technology‑readiness levels (TRL), exposing a “maturity paradox” where scientific performance outpaces real‑world deployment readiness.
- Policy actions should focus on broadening support for emerging topics (e.g., single‑cell, multimodal models), strengthening coordinated data infrastructure, funding European foundation AI models as public goods, and creating assessment frameworks that marry scientific maturity with technology readiness and clear regulatory pathways.
Current Landscape of Biological AI
Biological AI is reshaping research across genomics, proteomics, and drug discovery, with models trained on DNA, RNA, and protein data advancing at uneven speeds. As the JRC report Artificial Intelligence for Biology: Capabilities, Readiness, and Policy Implications notes, “Biological Artificial Intelligence (AI) models are advancing fastest in data‑rich areas like protein structure, while progressing at a slower pace where data is less abundant and structured, such as single‑cell biology.” This disparity stems from the availability of well‑curated, large‑scale repositories for proteins versus the fragmented, heterogeneous nature of single‑cell and clinical datasets.
Protein‑Centric Advances
The most mature AI applications lie in protein‑centric tasks: structure prediction, functional annotation, and de novo molecular design. Breakthroughs such as AlphaFold and ESM3 illustrate what sustained community effort and curated data can achieve. The report highlights that “Such progress of protein models (eg. AlphaFold) was made possible by decades-long commitment of a dedicated research community, and thanks to curated data from repositories including the Protein Data Bank and UniProt, supported by European Research Infrastructures like the European Molecular Biology Laboratory (EMBL).” These resources have enabled Europe to contribute significantly to the global protein‑modeling landscape, even though the field remains dominated by a handful of non‑EU actors.
Challenges in Single‑Cell Biology
In contrast, single‑cell biology—critical for tumour characterization and immunotherapy response prediction—remains under‑developed. The primary bottleneck is “limited and less standardised data,” which complicates model training, reproducibility, and benchmarking. Without cohesive data standards, researchers struggle to transfer findings across studies, and AI models in this domain often lack the robustness needed for clinical translation. The report warns that this gap could impede the EU’s ability to leverage AI for precision medicine and related public‑health goals.
Maturity versus Technology Readiness
A central insight of the JRC analysis is the distinction between domain maturity (how well a model performs on scientific benchmarks) and technology readiness (its suitability for real‑world deployment). High‑profile models like AlphaFold and ESM3 are “domain‑mature but remain at low‑to‑mid TRL.” The authors coin this mismatch the “maturity paradox,” underscoring that strong predictive performance does not guarantee validated pipelines for clinical or industrial use. None of the surveyed models has undergone an integrated readiness assessment, raising concerns about unchecked deployment, especially given potential dual‑use risks such as pathogen design or toxin engineering.
Building Blocks: Data, Compute, Collaboration
Developing robust biological AI hinges on three pillars: training data, computational infrastructure, and collaboration. Data availability is highly uneven; protein models benefit from standardized sets like UniRef, whereas RNA, single‑cell, and clinical areas rely on a “smaller and more varied set of sources.” Moreover, an increasing reliance on synthetic data from the AlphaFold Database signals a shift toward predicted—rather than experimentally derived—information, which may affect model generalisability.
Compute resources also show a disparity: industry typically accesses larger hardware budgets and longer training windows than academia, widening the resource gap. Nevertheless, Europe’s high‑performance computing capacity via the EuroHPC Joint Undertaking (EuroHPC JU) and the newly launched AI Factories provides a solid foundation for bridging this divide, provided access policies are equitable.
Collaboration patterns reveal that academia contributes to 85 % of surveyed models, while industry participates in nearly 40 %. However, only 17 % of industry‑only models release their training code, hinting at a growing trend toward proprietary secrecy as private sector involvement rises. Geographically, intra‑EU collaboration lags behind partnerships with the US, China, and the UK; among the top 20 global model developers, the sole EU representative is the Technical University of Munich.
Policy Recommendations for the EU
To harness its strengths and address identified weaknesses, the report puts forward four actionable recommendations:
- Broaden support for emerging topics – fund research in single‑cell biology, multimodal models, and other nascent areas while aligning AI for biology with EU priorities in health, food security, and the circular bioeconomy.
- Strengthen biological data infrastructure – improve coordination among repositories, implement transparent data‑quality assessments, and foster interoperability to reduce fragmentation.
- Bolster European foundation AI models as public goods – invest in open‑source, EU‑based foundation models that encourage strategic intra‑EU collaboration and reduce reliance on non‑European proprietary systems.
- Develop integrated readiness frameworks – combine domain‑specific maturity assessments with technology‑readiness levels, incorporate clinically relevant benchmarks, and establish clearer regulatory pathways to validate models before deployment.
By acting on these points, the EU can close the maturity‑readiness gap, mitigate biosecurity and dual‑use risks, and position itself as a leader in trustworthy, impactful biological AI.
https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/biological-ai-models-new-paradigms-leverage-languages-life-2026-08-20_en